Conference Call to Be Held Monday, August 15, 2016 at 4:30 pm Eastern Time
SEATTLE, WA--(Marketwired - Aug 12, 2016) - Atossa Genetics Inc. (
Dr. Steve Quay, President and CEO, commented, "We are encouraged by our continued progress on both our recently announced new drug development program with oral endoxifen and our ongoing Phase 2 clinical trial of intraductal fulvestrant administration in women with ductal carcinoma in situ (DCIS) or invasive breast cancer." Dr. Quay continued, "With our recently announced settlement with Besins Healthcare, we will have an additional $1.76 million to commit to executing on the promise of our two exciting drug developments programs. We have made substantial progress on both of our drug development programs: For oral endoxifen we have filed patent applications; contracted for the initial drug supply; and identified its initial indication -- breast cancer patients who are refractory to tamoxifen thereby getting little or no benefit from taking tamoxifen. Our Phase 2 clinical trial of intraductal fulvestrant is ongoing and is progressing as planned."
Recent Corporate Developments
Atossa's important recent developments include the following:
Q2 2016 Financial Results
Total operating expenses were $1.7 million and $4.0 million for the three months and six months ended June 30, 2016, respectively, consisting of general and administrative (G&A) expenses of $1.6 million and $3.7 million, respectively, and R&D expenses of $169,000 and $319,000, respectively. As a result of the sale of NRLBH in December 2015, operating expenses related to the NRLBH are presented separately as discontinued operations for the three months and six months ended June 30, 2015.
Operating expenses from continuing operations for the three months and six months ended June 30, 2016 decreased $1.5 million and $2.4 million, or 45.7% and 37.1%, respectively, from $3.2 million and $6.4 million for the three months and six months ended June 30, 2015, respectively, which consisted of G&A expenses of $2.4 million and $4.8 million, respectively, R&D expenses of $373,000 and $939,000, respectively, and selling expenses of $343,000 and $689,000, respectively. The decrease in operating expenses is mainly attributed to the 2015 launch of new devices and services which are not being pursued in 2016 and investing more in new R&D programs in the first quarter of 2015 compared to 2016.
For the three months and six months ended June 30, 2016, the Company recorded a net loss of $1.7 million and $4.0 million, respectively.
Conference Call Information
Management will host a business update conference call on Monday, August 15, 2016 at 4:30 pm eastern time to review Second Quarter ended June 30, 2016 financial results and provide a company update. Following management's formal remarks, there will be a question and answer session.
To listen to the call by phone, interested parties within the U.S. should call 1-844-824-3830 and International callers should call 1-412-317-5140. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar.
A replay of the call will be available approximately one hour after the end of the call through September 15, 2016. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10091229.
About Atossa Genetics
Atossa Genetics Inc. is developing novel and locally-administered pharmaceuticals to address breast conditions, including cancer. For more information, please visit www.atossagenetics.com.
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
|ATOSSA GENETICS INC.|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30,||December 31,|
|Cash and cash equivalents||$||1,190,866||$||3,715,895|
|Other current assets||-||110,663|
|Total current assets||1,454,995||4,294,851|
|Furniture and equipment, net||114,235||171,568|
|Intangible assets, net||1,447,010||1,700,565|
|Liabilities and Stockholders' Equity|
|Other current liabilities||22,734||64,128|
|Total current liabilities||874,265||2,501,587|
|Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding||-||-|
|Common stock - $.001 par value; 75,000,000 shares authorized, 39,569,510 and 32,657,257 shares issued and outstanding||39,569||32,657|
|Additional paid-in capital||57,355,571||54,643,940|
|Total stockholders' equity||2,410,354||3,741,734|
|Total liabilities and stockholders' equity||$||3,284,619||$||6,243,321|
|ATOSSA GENETICS INC.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|For the Three Months Ended
|For The Six Months Ended
|Cost of revenue||-||-||-||-|
|Research and development||168,992||373,474||318,963||939,275|
|General and administrative||1,553,391||2,453,751||3,730,960||4,807,687|
|Total operating expenses||1,722,383||3,170,547||4,049,923||6,436,130|
|Other income (expense)||-||48,659||-||40,155|
|Loss before income taxes||(1,722,383||)||(3,121,888||)||(4,049,923||)||(6,395,975||)|
|Loss from continuing operations||(1,722,383||)||(3,121,888||)||(4,049,923||)||(6,395,975||)|
|Loss from discontinued operations||-||(23,438||)||-||(84,642||)|
|Loss per common share - basic and diluted||$||(0.05||)||$||(0.11||)||$||(0.12||)||$||(0.25||)|
|Weighted average shares outstanding, basic & diluted||34,550,826||27,686,202||33,058,066||25,805,293|
Atossa Genetics Company Contact:
Atossa Genetics Inc.
CFO and General Counsel
Investor Relations Contact
377 Oak Street
Garden City, NY 11530